Our Blog Melanoma360

Blog - Melanoma360

Featured image for “2026 National Sunscreen Partner”
04/07/2026

2026 National Sunscreen Partner

We are proud to share that burnd Sunscreen has joined AIM at Melanoma as our 2026 National Sunscreen Partner. This…
Blog - Melanoma360
Philanthropy
Featured image for “Young Adult Cancer & Mental Health”
04/07/2026

Young Adult Cancer & Mental Health

In this episode of Beyond the Clinic: Living Well with Melanoma, host Dr. Samantha Siegel sits down with Dr. Victoria…
Blog - Melanoma360
Podcast
Featured image for “Uveal Melanoma Webinar: Part II — Navigating Treatment in the Metastatic Setting                     ”
04/02/2026

Uveal Melanoma Webinar: Part II — Navigating Treatment in the Metastatic Setting                     

Presented in partnership with Save Your Skin Foundation and Ocumel CanadaOcumel Canada (OC), is powered by Save Your Skin Foundation,…
Blog - Melanoma360
Featured image for “Wade Watson, Stage III Melanoma Survivor”
03/26/2026

Wade Watson, Stage III Melanoma Survivor

A Diagnosis That Changed Everything In early 2021, Wade Watson and his father received life-changing news just weeks apart. His…
Blog - Melanoma360
Survivor Stories
Featured image for “Advocates Renew Call for RP1 Approval”
03/26/2026

Advocates Renew Call for RP1 Approval

As the U.S. Food and Drug Administration approaches a pivotal decision on a potential new treatment for advanced melanoma, patient…
Blog - Melanoma360
Melanoma Research
Featured image for “Cancer is More Than a Diagnosis: Mind, Meaning, and Healing”
03/03/2026

Cancer is More Than a Diagnosis: Mind, Meaning, and Healing

Cancer is often spoken about in terms of diagnosis, treatment plans, and survival rates. But there is a quieter, more…
Blog - Melanoma360
Podcast
Featured image for “Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® ”
02/19/2026

Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® 

San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “FDA Responds to Patient Advocacy on RP1 + Nivolumab”
02/05/2026

FDA Responds to Patient Advocacy on RP1 + Nivolumab

As part of our continued advocacy for patients with advanced melanoma, we are sharing the U.S. Food and Drug Administration’s…
Blog - Melanoma360
Melanoma Research
Featured image for “Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma”
02/05/2026

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb.…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up”
01/23/2026

Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up

By Kamal Choudhury and Mariam E SunnyJanuary 20, 2026 3:52 PM EST Jan 20 (Reuters) – Moderna (MRNA.O), opens new tab and Merck…
Blog - Melanoma360
Melanoma Research
04/07/2026

2026 National Sunscreen Partner

We are proud to share that burnd Sunscreen has joined AIM at Melanoma as our 2026 National Sunscreen Partner. This…
Featured image for “2026 National Sunscreen Partner”
Blog - Melanoma360
 | 
Philanthropy
04/07/2026

Young Adult Cancer & Mental Health

In this episode of Beyond the Clinic: Living Well with Melanoma, host Dr. Samantha Siegel sits down with Dr. Victoria…
Featured image for “Young Adult Cancer & Mental Health”
Blog - Melanoma360
 | 
Podcast
04/02/2026

Uveal Melanoma Webinar: Part II — Navigating Treatment in the Metastatic Setting                     

Presented in partnership with Save Your Skin Foundation and Ocumel CanadaOcumel Canada (OC), is powered by Save Your Skin Foundation,…
Featured image for “Uveal Melanoma Webinar: Part II — Navigating Treatment in the Metastatic Setting                     ”
Blog - Melanoma360
03/26/2026

Wade Watson, Stage III Melanoma Survivor

A Diagnosis That Changed Everything In early 2021, Wade Watson and his father received life-changing news just weeks apart. His…
Featured image for “Wade Watson, Stage III Melanoma Survivor”
Blog - Melanoma360
 | 
Survivor Stories
03/26/2026

Advocates Renew Call for RP1 Approval

As the U.S. Food and Drug Administration approaches a pivotal decision on a potential new treatment for advanced melanoma, patient…
Featured image for “Advocates Renew Call for RP1 Approval”
Blog - Melanoma360
 | 
Melanoma Research
03/03/2026

Cancer is More Than a Diagnosis: Mind, Meaning, and Healing

Cancer is often spoken about in terms of diagnosis, treatment plans, and survival rates. But there is a quieter, more…
Featured image for “Cancer is More Than a Diagnosis: Mind, Meaning, and Healing”
Blog - Melanoma360
 | 
Podcast
02/19/2026

Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® 

San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…
Featured image for “Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® ”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
02/05/2026

FDA Responds to Patient Advocacy on RP1 + Nivolumab

As part of our continued advocacy for patients with advanced melanoma, we are sharing the U.S. Food and Drug Administration’s…
Featured image for “FDA Responds to Patient Advocacy on RP1 + Nivolumab”
Blog - Melanoma360
 | 
Melanoma Research
02/05/2026

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb.…
Featured image for “Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
01/23/2026

Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up

By Kamal Choudhury and Mariam E SunnyJanuary 20, 2026 3:52 PM EST Jan 20 (Reuters) – Moderna (MRNA.O), opens new tab and Merck…
Featured image for “Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up”
Blog - Melanoma360
 | 
Melanoma Research